CLINICAL TRIALS PROFILE FOR CARBOPROST TROMETHAMINE

All Clinical Trials for CARBOPROST TROMETHAMINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05518812 ↗	Carboprost (Hemabate) for Fibroid Resection	Recruiting	Northwestern University	Early Phase 1	2022-07-12	The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).
NCT02722356 ↗	Outcomes After the Implementation of a New Oxytocin Protocol	Completed	C.R.Darnall Army Medical Center	N/A	2016-04-01	The proposed study is a prospective, randomized, active control, open label study. One hundred sixty subjects undergoing elective cesarean section will be randomly assigned to one of two groups (n = 80 per group): the oxytocin protocol group or the standard practice group. The oxytocin protocol group will receive oxytocin boluses along with a regulated infusion according to a stepwise algorithm following delivery of the placenta. The standard practice group will receive oxytocin via a free flowing ("wide-open") infusion with a concentration of 30 IU per 500 mL of 0.9% normal saline following the delivery of the placenta. Primary outcomes include uterine tone (adequate or inadequate) as assessed by the surgeon, amount of time required to establish adequate uterine tone following the delivery of the infant, total dose of oxytocin required to establish adequate uterine tone, and total calculated blood loss based on pre-operative and post-operative hematocrit concentrations. Secondary outcomes include total estimated blood loss as agreed upon by the surgeon and the anesthesia provider, use of additional uterotonic drugs, mean arterial pressure, and incidence of oxytocin side effects (nausea, chest tightness/pain, and ST-segment changes).
NCT00891150 ↗	Oxytocin to Decrease Blood Loss During Cesarean Section	Completed	American University of Beirut Medical Center	N/A	2012-07-01	The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed.

Clinical Trial Conditions for CARBOPROST TROMETHAMINE

Condition Name

Condition Name for CARBOPROST TROMETHAMINE
Intervention	Trials
Complications; Cesarean Section	2
Fibroid Uterus	1
Gynecologic Disease	1
Leiomyoma, Uterine	1

Condition MeSH

Condition MeSH for CARBOPROST TROMETHAMINE
Intervention	Trials
Myofibroma	1
Leiomyoma	1
Hemorrhage	1

Clinical Trial Locations for CARBOPROST TROMETHAMINE

Trials by Country

+

−

Trials by Country for CARBOPROST TROMETHAMINE
Location	Trials
Lebanon	1
United States	1

Trials by US State

+

−

Trials by US State for CARBOPROST TROMETHAMINE
Location	Trials
Illinois	1

Clinical Trial Progress for CARBOPROST TROMETHAMINE

Clinical Trial Phase

Clinical Trial Phase for CARBOPROST TROMETHAMINE
Clinical Trial Phase	Trials
N/A	2
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for CARBOPROST TROMETHAMINE
Clinical Trial Phase	Trials
Completed	2
Recruiting	1

Clinical Trial Sponsors for CARBOPROST TROMETHAMINE

Sponsor Name

Sponsor Name for CARBOPROST TROMETHAMINE
Sponsor	Trials
Northwestern University	1
American University of Beirut Medical Center	1
C.R.Darnall Army Medical Center	1

Sponsor Type

Sponsor Type for CARBOPROST TROMETHAMINE
Sponsor	Trials
Other	2
U.S. Fed	1

Carboprost Tromethamine: Clinical Trials, Market Analysis, and Projections

What is Carboprost Tromethamine?

Carboprost tromethamine is a prostaglandin analog used primarily in the medical field for two main applications: treating postpartum hemorrhage and inducing abortion. It works by causing the uterus to contract, which helps in controlling bleeding and inducing labor.

Clinical Trials and Efficacy

Postpartum Hemorrhage Treatment

Clinical trials have shown that carboprost tromethamine is effective in treating postpartum hemorrhage. A study involving 1,040 participants compared the efficacy of carboprost tromethamine with methylergonovine, another uterotonic agent. The results indicated no significant difference in uterine tone scores 10 minutes after administration, but both drugs were effective in managing uterine atony and postpartum hemorrhage[4].

Pharmacokinetics

In a study where five women were treated with a single injection of 250 micrograms of carboprost tromethamine postpartum, the highest concentration of the drug was observed between 15 to 60 minutes after administration. The levels decreased to less than the preceding peak values by two hours after each injection[1].

Market Analysis

Global Market Size and Growth

The global carboprost tromethamine market is projected to grow significantly over the next few years. As of 2022, the market size was valued at approximately USD 1.46 billion and is expected to reach USD 1.85 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of around 3.06%[2].

Market Segmentation

By Application

The market is segmented into two main applications: postpartum hemorrhage treatment and pregnancy abortion. The postpartum hemorrhage treatment segment is expected to capture the largest market share during the forecast period due to the increasing incidence of postpartum hemorrhage[2][5].

By Distribution Channel

Hospital pharmacies dominate the distribution channel segment, reflecting the critical role hospitals play in providing comprehensive obstetric care. The availability of carboprost tromethamine in hospital settings is crucial for managing obstetric emergencies[3].

Regional Analysis

The North American region is expected to dominate the market due to the high frequency of postpartum hemorrhage, rising pregnancy rates, and advancements in pharmaceutical innovation and research. The Europe market is also growing steadily, driven by an advanced healthcare system and ongoing research in postpartum hemorrhage treatments. The Asia-Pacific region is the fastest-growing market, driven by government and medical facility efforts to improve maternal healthcare[2][5].

Market Projections

Future Growth

The global carboprost tromethamine market is anticipated to continue growing at a CAGR of around 3.40% to 3.7% from 2024 to 2032. By 2032, the market is projected to reach approximately USD 2.09 billion[5][3].

Key Drivers

• Increasing Maternal Health Concerns: The growing incidence of postpartum hemorrhage and other childbirth-related issues drive the demand for carboprost tromethamine.
• Advancements in Healthcare Infrastructure: Global improvements in healthcare infrastructure and the availability of advanced medical facilities contribute to market growth.
• FDA Approvals and Regulatory Support: The increasing number of FDA approvals for carboprost tromethamine enhances its credibility and acceptance among healthcare providers[2][5][3].

Market Trends

• Rising Demand for Family Planning: Changes in social perspectives towards family planning and reproductive options are driving the demand for drugs like carboprost tromethamine.
• Government Policies and Healthcare Accessibility: Government policies and the accessibility of healthcare services, particularly those related to abortion and maternal care, influence market trends[3].

Key Players

The market is dominated by several key players, including Hikma Pharmaceuticals PLC, Pharmacia and Upjohn Company LLC (a division of Pfizer Inc.), Sandoz Inc. (a Novartis Division), LGM Pharma, Pfizer Inc., JHP Pharmaceuticals, LLC, and Sun Pharmaceutical Industries Ltd[5].

Conclusion

Carboprost tromethamine is a vital drug in the field of obstetrics, particularly for treating postpartum hemorrhage and inducing abortion. Clinical trials have demonstrated its efficacy, and market projections indicate significant growth driven by increasing maternal health concerns, advancements in healthcare infrastructure, and regulatory support.

Key Takeaways

• Clinical Efficacy: Carboprost tromethamine is effective in treating postpartum hemorrhage and inducing abortion.
• Market Growth: The global market is projected to grow at a CAGR of around 3.06% to 3.7% from 2023 to 2032.
• Regional Dominance: North America is expected to dominate the market, followed by Europe and the Asia-Pacific region.
• Key Drivers: Increasing maternal health concerns, advancements in healthcare infrastructure, and FDA approvals drive market growth.
• Market Trends: Rising demand for family planning and changes in government policies influence market trends.

FAQs

What is the primary use of carboprost tromethamine?

Carboprost tromethamine is primarily used to treat postpartum hemorrhage and to induce abortion.

What is the expected market size of carboprost tromethamine by 2030?

The global carboprost tromethamine market is expected to reach approximately USD 1.85 billion by 2030[2].

Which region dominates the carboprost tromethamine market?

The North American region is expected to dominate the market due to the high frequency of postpartum hemorrhage and advancements in pharmaceutical innovation and research[2][5].

What are the key drivers of the carboprost tromethamine market?

The key drivers include increasing maternal health concerns, advancements in healthcare infrastructure, and FDA approvals for the drug[2][5][3].

Which companies are the key players in the carboprost tromethamine market?

Key players include Hikma Pharmaceuticals PLC, Pharmacia and Upjohn Company LLC, Sandoz Inc., LGM Pharma, Pfizer Inc., JHP Pharmaceuticals, LLC, and Sun Pharmaceutical Industries Ltd[5].

Sources

1. Hemabate® carboprost tromethamine injection, USP - FDA Label.
2. Global Carboprost Tromethamine Market Size Is Projected to Grow USD 1850 Million by 2030 with CAGR of 3.06% - GlobeNewswire.
3. At 3.7% CAGR, Global Carboprost Tromethamine Market Size Value to Be Worth USD 2,100.63 Million by 2032 - Polaris Market Research.
4. Second-Line Uterotonics for Uterine Atony: A Randomized Controlled Trial - PubMed.
5. Carboprost Tromethamine Market Trends, Growth, Forecast 2032 - Market Research Future.